said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. “We are also grateful for Pierre’s invaluable contributions. During his six years at Innate, he drove the advancement of several key assets to late-stage clinical development, which will have a lasting impact on the Company.”
Helt ålreit skussmål fra CEO i forrige selskap, hvor han sluttet i fjor sommer